September 6, 2017
GenomeWeb
“Greenwood Genetic Center announced today that it has signed an agreement to use FDNA’s Face2Gene next-generation phenotyping technology to gain insights into thousands of undiagnosed patients with rare diseases. Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses based on a database of more than 10,000 rare disease syndromes. Under the terms of the deal, GGC will use Face2Gene to analyze nearly 80,000 undiagnosed cases to generate actionable answers for these patients, identifying new syndrome-related clinical phenotypes, and making rare disease discoveries that can advance overall research. FDNA will use data from these analyses to strengthen its database of known diagnoses.”
The article describes that Greenwood Genetic Center has partnered with FDNA to utilize its advanced phenotyping technology, particularly the Face2Gene platform, for analyzing patients with rare diseases. Face2Gene harnesses artificial intelligence and deep learning to evaluate facial features, helping clinicians identify phenotypic markers indicative of genetic disorders. By integrating this cutting-edge technology, the Greenwood Genetic Center aims to enhance the accuracy and speed of rare disease diagnoses. This collaboration highlights the growing importance and effectiveness of AI-driven phenotyping technology in genetics, providing a more precise decision support tool that benefits patients through early identification and tailored treatment strategies.
